Showing results (71-80 of 84) with videos related to
Sort By:
Pageof 9
BMC Nephrology|July 18, 2018
Serum free light chain levels and renal function at diagnosis in patients with multiple myelomaPunit Yadav, Paul Cockwell, Mark Cook, et al.Blood Advances|September 12, 2025
mTOR activity and metabolic reprogramming of CD8+ T cells is impaired under hypoxia and within the multiple myeloma bone marrowTaylor Fulton-Ward, Nancy Gudgeon, Isaac Thirlwell, et al.Journal of Cellular and Molecular Medicine|May 22, 2025
The Overexpression of Collagen Receptor DDR1 is Associated With Chromosome Instability and Aneuploidy in Diffuse Large B-Cell LymphomaSandra Margielewska-Davies, Matthew Pugh, Eszter Nagy, et al.Blood|April 16, 2014
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcomeAnnamaria Brioli, Hannah Giles, Charlotte Pawlyn, et al.Blood|March 29, 2020
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trialAndrew H Wei, Pau Montesinos, Vladimir Ivanov, et al.Blood Cancer Journal|October 2, 2021
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.Blood Advances|June 5, 2023
Uptake of long-chain fatty acids from the bone marrow suppresses CD8+ T-cell metabolism and function in multiple myelomaNancy Gudgeon, Hannah Giles, Emma L Bishop, et al.Journal of Hepatology|October 3, 2024
Plasma exchange does not improve overall survival in patients with acute liver failure in a real-world cohortLaura Burke, William Bernal, Tasneem Pirani, et al.Haematologica|June 6, 2024
Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphomaNicholas Davies, Tegan Francis, Ceri Oldreive, et al.Blood Advances|December 1, 2023
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AMLCarlos Jimenez-Chillon, Jad Othman, David Taussig, et al.Pageof 9